
    
      This is a Phase 1 study in healthy adult participants. The study will consist of 2 single
      ascending dose (Cohorts 1 and 2) and 4 multiple ascending dose cohorts (Cohorts 3 to 6).
      Participants will be randomly assigned to each of the 6 cohorts to receive either single or
      multiple doses of ALXN1830 subcutaneous (SC) or single or multiple doses of placebo SC.
      Cohort 6 will enroll only healthy participants of Japanese descent who will be dosed
      according to the highest tolerated dose (HTD) established in the non-Japanese cohorts.
    
  